Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer.
Journal: JNCI cancer spectrum
Published: April 01, 2025
Pre- or post-chemotherapy: effect on PSMA uptake.
Journal: EJNMMI research
Published: January 23, 2025
Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: April 15, 2024
Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection.
Journal: Frontiers in oncology
Published: February 08, 2024
Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 19, 2023
Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.
Journal: European urology
Published: December 05, 2022
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.
Journal: JAMA oncology
Published: September 16, 2021
Outcomes after high-dose radiation in the management of neuroendocrine neoplasms.
Journal: PloS one
Published: March 19, 2021
The Role of PSMA PET/CT and PET/MRI in the Initial Staging of Prostate Cancer.
Journal: European urology focus
Published: January 08, 2021
Factors Predicting Metastatic Disease in 68Ga-PSMA-11 PET-Positive Osseous Lesions in Prostate Cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 19, 2019
Last Updated: 09/26/2026